Adjuvant Chemotherapy in Patients With Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy
JAMA Oncology Author Interviews
Release Date: 12/08/2022
Proportional Sedation for Persistent Agitated Delirium in Palliative Care
JAMA Oncology Author Interviews
Interview with David Hui, MD, and Eduardo Bruera, MD, authors of Proportional Sedation for Persistent Agitated Delirium in Palliative Care: A Randomized Clinical Trial. Hosted by Vivek Subbiah, MD.
info_outline
New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance
JAMA Oncology Author Interviews
Interview with Thorir Einarsson Long, MD, PhD, and Ola Landgren, MD, PhD, authors of New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance. Hosted by Vivek Subbiah, MD.
info_outline
Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury
JAMA Oncology Author Interviews
Interview with Shruti Gupta, MD, MPH, author of Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury. Hosted by Vivek Subbiah, MD.
info_outline
Accelerated Aging in Survivors of Childhood Cancer
JAMA Oncology Author Interviews
Interview with Jennifer M. Yeh, PhD, and Lisa R. Diller, MD, authors of Accelerated Aging in Survivors of Childhood Cancer—Early Onset and Excess Risk of Chronic Conditions. Hosted by Vivek Subbiah, MD.
info_outline
Academic-Community Partnership and Deaths in Promyelocytic Leukemia
JAMA Oncology Author Interviews
Interview with Anand P. Jillella, MD, author of Academic-Community Partnership and Deaths in Promyelocytic Leukemia: The Nonrandomized ECOG-ACRIN EA9131 Trial. Hosted by Vivek Subbiah, MD.
info_outline
Intracranial Outcomes in Melanoma Brain Metastases After Anti–PD-1 Therapy
JAMA Oncology Author Interviews
Interview with Michael A. Postow, MD, author of Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy. Hosted by Vivek Subbiah, MD.
info_outline
Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020
JAMA Oncology Author Interviews
Interview with Katrina A. B. Goddard, PhD, author of Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020. Hosted by Vivek Subbiah, MD.
info_outline
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
JAMA Oncology Author Interviews
Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD.
info_outline
Anti–PD-L1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma
JAMA Oncology Author Interviews
Interview with Maria E. Cabanillas, MD, author of Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. Hosted by Vivek Subbiah, MD.
info_outline
Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer
JAMA Oncology Author Interviews
Interview with Eileen M. O’Reilly, MD, author of Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer. Hosted by Vivek Subbiah, MD.
info_outlineInterview with Marco Del Chiaro, MD, PhD, author of Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy. Hosted by Jack West, MD.
Related Content: